Growth, clinical and neurodevelopmental outcomes at school age are similar for children who received 1-year lamivudine or lopinavir/ritonavir HIV prophylaxis in early life

Abstract In the ANRS 12174 trial, HIV-exposed uninfected African neonates who received lopinavir-ritonavir (LPV/r) prophylaxis for 1 year exhibited slower growth from birth to week 50 compared with those receiving lamivudine (3TC). We assessed whether this difference in growth persisted over time, a...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Nicolas Nagot, Mandisa Singata-Madliki, Amandine Cournil, Joyce Nalugya, Souleymane Tassembedo, Catherine Quillet, Melany W. Tonga, James Tumwine, Nicolas Meda, Chipepo Kankasa, Mwiya Mwiya, Paul Bangirana, Marianne Peries, Joanne Batting, Ingunn M. S. Engebretsen, Thorkild Tylleskär, Philippe Vande Perre, Grace Ndeezi, Jean-Pierre Molès
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/3c2f1f5d320041d796767d8a985af567
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:3c2f1f5d320041d796767d8a985af567
record_format	dspace
spelling	oai:doaj.org-article:3c2f1f5d320041d796767d8a985af5672021-12-02T14:06:49ZGrowth, clinical and neurodevelopmental outcomes at school age are similar for children who received 1-year lamivudine or lopinavir/ritonavir HIV prophylaxis in early life10.1038/s41598-021-82762-82045-2322https://doaj.org/article/3c2f1f5d320041d796767d8a985af5672021-02-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-82762-8https://doaj.org/toc/2045-2322Abstract In the ANRS 12174 trial, HIV-exposed uninfected African neonates who received lopinavir-ritonavir (LPV/r) prophylaxis for 1 year exhibited slower growth from birth to week 50 compared with those receiving lamivudine (3TC). We assessed whether this difference in growth persisted over time, and was accompanied by differences in neuropsychological and clinical outcomes. Between February 2017 and February 2018, we conducted a cross-sectional clinical evaluation among former trial participants who completed the 50-week follow-up and who were not HIV-infected. In addition to clinical examination, neuropsychological outcomes were assessed using the tests Kaufman-ABCII, Test of Variables of Attention, Movement Assessment Battery for Children and the Strengths and Difficulties questionnaire, parent version. Of 1101 eligible children, aged 5–7 years, 553 could be traced and analysed (274 in the LPV/r and 279 in the 3TC groups). Growth, clinical and neuropsychological outcomes did not differ between treatment groups. At school age, children exposed to LPV/r and 3TC at birth for 1 year had comparable growth and neuropsychological outcomes without evidence of long-term side-effects of LPV/r. It provides reassuring data on clinical outcomes for all HIV-infected children treated with this antiretroviral drug in early life.Nicolas NagotMandisa Singata-MadlikiAmandine CournilJoyce NalugyaSouleymane TassembedoCatherine QuilletMelany W. TongaJames TumwineNicolas MedaChipepo KankasaMwiya MwiyaPaul BangiranaMarianne PeriesJoanne BattingIngunn M. S. EngebretsenThorkild TylleskärPhilippe Vande PerreGrace NdeeziJean-Pierre MolèsNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Nicolas Nagot Mandisa Singata-Madliki Amandine Cournil Joyce Nalugya Souleymane Tassembedo Catherine Quillet Melany W. Tonga James Tumwine Nicolas Meda Chipepo Kankasa Mwiya Mwiya Paul Bangirana Marianne Peries Joanne Batting Ingunn M. S. Engebretsen Thorkild Tylleskär Philippe Vande Perre Grace Ndeezi Jean-Pierre Molès Growth, clinical and neurodevelopmental outcomes at school age are similar for children who received 1-year lamivudine or lopinavir/ritonavir HIV prophylaxis in early life
description	Abstract In the ANRS 12174 trial, HIV-exposed uninfected African neonates who received lopinavir-ritonavir (LPV/r) prophylaxis for 1 year exhibited slower growth from birth to week 50 compared with those receiving lamivudine (3TC). We assessed whether this difference in growth persisted over time, and was accompanied by differences in neuropsychological and clinical outcomes. Between February 2017 and February 2018, we conducted a cross-sectional clinical evaluation among former trial participants who completed the 50-week follow-up and who were not HIV-infected. In addition to clinical examination, neuropsychological outcomes were assessed using the tests Kaufman-ABCII, Test of Variables of Attention, Movement Assessment Battery for Children and the Strengths and Difficulties questionnaire, parent version. Of 1101 eligible children, aged 5–7 years, 553 could be traced and analysed (274 in the LPV/r and 279 in the 3TC groups). Growth, clinical and neuropsychological outcomes did not differ between treatment groups. At school age, children exposed to LPV/r and 3TC at birth for 1 year had comparable growth and neuropsychological outcomes without evidence of long-term side-effects of LPV/r. It provides reassuring data on clinical outcomes for all HIV-infected children treated with this antiretroviral drug in early life.
format	article
author	Nicolas Nagot Mandisa Singata-Madliki Amandine Cournil Joyce Nalugya Souleymane Tassembedo Catherine Quillet Melany W. Tonga James Tumwine Nicolas Meda Chipepo Kankasa Mwiya Mwiya Paul Bangirana Marianne Peries Joanne Batting Ingunn M. S. Engebretsen Thorkild Tylleskär Philippe Vande Perre Grace Ndeezi Jean-Pierre Molès
author_facet	Nicolas Nagot Mandisa Singata-Madliki Amandine Cournil Joyce Nalugya Souleymane Tassembedo Catherine Quillet Melany W. Tonga James Tumwine Nicolas Meda Chipepo Kankasa Mwiya Mwiya Paul Bangirana Marianne Peries Joanne Batting Ingunn M. S. Engebretsen Thorkild Tylleskär Philippe Vande Perre Grace Ndeezi Jean-Pierre Molès
author_sort	Nicolas Nagot
title	Growth, clinical and neurodevelopmental outcomes at school age are similar for children who received 1-year lamivudine or lopinavir/ritonavir HIV prophylaxis in early life
title_short	Growth, clinical and neurodevelopmental outcomes at school age are similar for children who received 1-year lamivudine or lopinavir/ritonavir HIV prophylaxis in early life
title_full	Growth, clinical and neurodevelopmental outcomes at school age are similar for children who received 1-year lamivudine or lopinavir/ritonavir HIV prophylaxis in early life
title_fullStr	Growth, clinical and neurodevelopmental outcomes at school age are similar for children who received 1-year lamivudine or lopinavir/ritonavir HIV prophylaxis in early life
title_full_unstemmed	Growth, clinical and neurodevelopmental outcomes at school age are similar for children who received 1-year lamivudine or lopinavir/ritonavir HIV prophylaxis in early life
title_sort	growth, clinical and neurodevelopmental outcomes at school age are similar for children who received 1-year lamivudine or lopinavir/ritonavir hiv prophylaxis in early life
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/3c2f1f5d320041d796767d8a985af567
work_keys_str_mv	AT nicolasnagot growthclinicalandneurodevelopmentaloutcomesatschoolagearesimilarforchildrenwhoreceived1yearlamivudineorlopinavirritonavirhivprophylaxisinearlylife AT mandisasingatamadliki growthclinicalandneurodevelopmentaloutcomesatschoolagearesimilarforchildrenwhoreceived1yearlamivudineorlopinavirritonavirhivprophylaxisinearlylife AT amandinecournil growthclinicalandneurodevelopmentaloutcomesatschoolagearesimilarforchildrenwhoreceived1yearlamivudineorlopinavirritonavirhivprophylaxisinearlylife AT joycenalugya growthclinicalandneurodevelopmentaloutcomesatschoolagearesimilarforchildrenwhoreceived1yearlamivudineorlopinavirritonavirhivprophylaxisinearlylife AT souleymanetassembedo growthclinicalandneurodevelopmentaloutcomesatschoolagearesimilarforchildrenwhoreceived1yearlamivudineorlopinavirritonavirhivprophylaxisinearlylife AT catherinequillet growthclinicalandneurodevelopmentaloutcomesatschoolagearesimilarforchildrenwhoreceived1yearlamivudineorlopinavirritonavirhivprophylaxisinearlylife AT melanywtonga growthclinicalandneurodevelopmentaloutcomesatschoolagearesimilarforchildrenwhoreceived1yearlamivudineorlopinavirritonavirhivprophylaxisinearlylife AT jamestumwine growthclinicalandneurodevelopmentaloutcomesatschoolagearesimilarforchildrenwhoreceived1yearlamivudineorlopinavirritonavirhivprophylaxisinearlylife AT nicolasmeda growthclinicalandneurodevelopmentaloutcomesatschoolagearesimilarforchildrenwhoreceived1yearlamivudineorlopinavirritonavirhivprophylaxisinearlylife AT chipepokankasa growthclinicalandneurodevelopmentaloutcomesatschoolagearesimilarforchildrenwhoreceived1yearlamivudineorlopinavirritonavirhivprophylaxisinearlylife AT mwiyamwiya growthclinicalandneurodevelopmentaloutcomesatschoolagearesimilarforchildrenwhoreceived1yearlamivudineorlopinavirritonavirhivprophylaxisinearlylife AT paulbangirana growthclinicalandneurodevelopmentaloutcomesatschoolagearesimilarforchildrenwhoreceived1yearlamivudineorlopinavirritonavirhivprophylaxisinearlylife AT marianneperies growthclinicalandneurodevelopmentaloutcomesatschoolagearesimilarforchildrenwhoreceived1yearlamivudineorlopinavirritonavirhivprophylaxisinearlylife AT joannebatting growthclinicalandneurodevelopmentaloutcomesatschoolagearesimilarforchildrenwhoreceived1yearlamivudineorlopinavirritonavirhivprophylaxisinearlylife AT ingunnmsengebretsen growthclinicalandneurodevelopmentaloutcomesatschoolagearesimilarforchildrenwhoreceived1yearlamivudineorlopinavirritonavirhivprophylaxisinearlylife AT thorkildtylleskar growthclinicalandneurodevelopmentaloutcomesatschoolagearesimilarforchildrenwhoreceived1yearlamivudineorlopinavirritonavirhivprophylaxisinearlylife AT philippevandeperre growthclinicalandneurodevelopmentaloutcomesatschoolagearesimilarforchildrenwhoreceived1yearlamivudineorlopinavirritonavirhivprophylaxisinearlylife AT gracendeezi growthclinicalandneurodevelopmentaloutcomesatschoolagearesimilarforchildrenwhoreceived1yearlamivudineorlopinavirritonavirhivprophylaxisinearlylife AT jeanpierremoles growthclinicalandneurodevelopmentaloutcomesatschoolagearesimilarforchildrenwhoreceived1yearlamivudineorlopinavirritonavirhivprophylaxisinearlylife
_version_	1718391956253442048

Growth, clinical and neurodevelopmental outcomes at school age are similar for children who received 1-year lamivudine or lopinavir/ritonavir HIV prophylaxis in early life

Ejemplares similares